Spain Blood Disease Industry Outlook 2022 - 2026

Key Market Indicators

Sales of Spanish blood and blood forming organs medicines are forecast to reach $2.7 billion by 2026, up from $2.1 billion in 2021. This implies an annual growth rate of 3.4% over the five-year period. Since 2009, the Spanish market has grown by 21.4% each year on average. In 2021, Spain was in fifth place, with South Korea leading the way at $2.1 billion. Germany, Italy and South Korea took spots two, three and four respectively. The number of hospital discharges related to anemia in Spain is expected to reach 26,850 by 2026, up from 26,150 in 2021 – a rise of 0.5% year-on-year. Since 1985, the Spanish demand has increased by 0.5% annually. In 2021, Australia led the way at 26,150 hospital discharges while Germany, the United Kingdom and Poland took positions two, three and four respectively.

Spain Blood Disease Market Data and Forecasts

Improve your Knowledge with the latest Indicators and Trends

• Pharmaceutical Advances: A Comprehensive Review of Sickle Cell Disease Pipeline Development

  Sickle cell disease (SCD) pharmaceutical landscape has significantly evolved over the past years, primarily driven by a greater understanding of the disease pathology and emerging innovative therapeutic paradigms. The shift towards patient-specific treatments, and the introduction of gene therapy and genome editing as potential curative options are remarkable indicators of...

  Discover more insights

• Molecular Blood Typing and Infectious Disease Markets: Exploring Supplier Shares and Innovative Strategies

  The sector dealing with molecular blood typing and grouping employs advanced immunohaematological techniques to ensure accurate blood transfusion, which is pivotal to patient safety. The market exhibits a growth trajectory, propelled by continuous technological advancements and a rising demand due to an increase in complex surgeries, trauma cases, and prenatal...

  Discover more insights

• Haemophilia: Unravelling Opportunities and Challenges in A & B Types Treatments

  The treatment landscape for Haemophilia A and B, genetic disorders causing impaired blood clotting, is considerably developed yet wavering. Prophylactic factor replacement therapy, the mainstay treatment, is efficacious but fraught with several challenges such as high frequency of infusions, risk of inhibitor development and high cost. Developments in extended half-life...

  Discover more insights

• Hemophilia Treatment Innovations: Exploring Pipeline Reviews and Global Clinical Trials

  The advancement of clinical science has brought an era of novel therapies for hemophilia like gene therapy and bispecific antibodies which are intended to not only treat but potentially cure the condition. A number of new treatments are in the pipeline, providing real hope for enhanced patient care and quality...

  Discover more insights

• Hematologic Disorders: Analyzing Market Trends in Myelofibrosis and Related Syndromes

  The Myelofibrosis market is influenced by several elements. New technologies, research methodologies, and advancements in pharmaceuticals contribute to the sector's dynamism. The increasing prevalence of the disease worldwide is also a significant factor, which leads to a growing demand for effective therapies. Regulatory policies and the role of government in...

  Discover more insights